An official website of the United States government
Study of XB010 in Subjects With Solid Tumors
Trial Status: active
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and
preliminary antitumor activity of XB010 as a single agent and in combination with
pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom
alternative therapies do not exist or available therapies are intolerable or no longer
effective.
Inclusion Criteria
- Age 18 years or older on the day of consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
- Adequate organ and marrow function.
- Cytologically or histologically and radiologically confirmed solid tumor that is
inoperable, locally advanced, metastatic, or recurrent.
- The Cohort Expansion stage will enroll subjects with multiple tumor types
(non-small cell lung cancer, hormone-receptor-positive breast cancer, head and
neck cancer, esophageal squamous cell, triple-negative breast cancer).
- Capable of understanding and complying with the protocol requirements and must have
signed the informed consent document.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06545331.
